Racura Oncology Demonstrates Key Equivalence for Reformulated Bisantrene Anti-Cancer Drug

Racura Oncology Demonstrates Key Equivalence for Reformulated Bisantrene Anti-Cancer Drug

Racura Oncology confirms reformulated bisantrene matches legacy drug exposure, supporting plans for a Phase 2b/3 AML trial.

Imelda Cotton
Imelda CottonJournalist
· 2 min read
In this storyRAC
In briefAt-a-glance3 takeaways
  • 01RC220 matched RC110 drug exposure in a canine study.
  • 02Equivalence supports leveraging RC110 clinical data for RC220.
  • 03Results back planned Phase 2b/3 AML trial.

Racura Oncology (ASX: RAC) has demonstrated the pharmacokinetic equivalence of two different formulations of anti-cancer drug (E,E)-bisantrene in a non-clinical bridging study on male canines.

When a drug such as (E,E)-bisantrene is reformulated with different inactive ingredients, evidence is needed that the new product delivers the same exposure to the active drug before experience with the older formulation can be relied on—this is known as pharmacokinetic equivalence.

Showing equivalent exposure in a human or animal study supports using earlier clinical experience to guide the development of a new formulation.

The Racura study found that the newly developed, proprietary reformulated RC220 can deliver equivalent systemic drug exposure to the earlier RC110 formulation, which has an extensive clinical history and was approved in France in 1988 for relapsed or refractory acute myeloid leukaemia (AML).

The results showed that ratios of peak and total drug exposure of RC220 fell within the pre-specified equivalence range of 0.80 to 1.25 (or 80% to 125%), the standard regulatory benchmark used to prove bioequivalence between drug formulations, supporting the use of the RC110 clinical dataset and dosing levels in the clinical development of RC220, including a planned Phase 2b/3 EMILI trial to treat AML.

Advertisement

Anti-Cancer Agent

Lead asset (E,E)-bisantrene is a clinically derisked small-molecule anti-cancer agent that acts by stabilising G4-DNA and RNA structures, driving potent inhibition of the c-MYC gene that is dysregulated in up to 70% of all cancers.

Racura is advancing the proprietary RC220 formulation to address significant unmet need across multiple MYC-driven oncology indications.

RC220 contains the same active pharmaceutical ingredient as RC110 but uses different non-drug ingredients.

It has been designed to allow safe peripheral intravenous delivery in the arm or leg, rather than strictly requiring a central line such as a catheter placed in a large vein near the heart, making it easier to administer in clinical settings.

Advertisement

Clinical Development

Racura chief executive officer Dr Daniel Tillett said the study results would guide the clinical development of RC220.

“The results showed the two formulations delivered equivalent exposure to (E,E)-bisantrene, providing an important bridge to the clinical experience with RC110 that produced a 40% response rate in two separate Phase 2 trials in heavily pre-treated AML patients,” he said.

“This study supports our plans to evaluate RC220 in a Phase 2b/3 EMILI trial for patients with AML as well as in our HARNESS lung cancer and CPACS solid tumour clinical programs.”

The planned trials will aim to deliver cardioprotection from potent chemotherapy medications such as doxorubicin, epirubicin, and daunorubicin, while also enhancing anti-cancer activity.

Subscribe · daily wire

Get the wire before the market opens.

The ASX small-cap stories that matter, filed before 9am AEST. Curated by the Small Caps desk.

Join 100,000+ investors. Unsubscribe anytime.
Imelda Cotton
About the author

Imelda Cotton

Journalist
View all articles

More like this

View all latest